Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Complement Component C3aR Antibody (hC3aRZ1) - BSA Free, Novus Biologicals™

Mouse Monoclonal Antibody
Supplier: Novus Biologicals NB100648350.025MG
Description
Complement Component C3aR Monoclonal specifically detects Complement Component C3aR in Human samples. It is validated for Flow Cytometry, Immunohistochemistry, Immunohistochemistry-Frozen.Specifications
Complement Component C3aR | |
Monoclonal | |
1 mg/mL | |
Flow Cytometry 1:10-1:20, Immunohistochemistry 1:10-1:500, Immunohistochemistry-Frozen 1:10-1:500 | |
Q16581 | |
C3AR1 | |
Recombinant human C3aR protein | |
0.025 mg | |
Primary | |
NB100-64835 recognizes the receptor for human complement component C3a (C3aR), a 55kD cell surface protein of the rhodopsin family of G protein-coupled seven-transmembrane receptors. C3a is an anaphylatoxin, which is a potent proinflammatory mediator that possesses immunoregulatory properties. C3a regulates inflammatory functions by binding to the C3a receptor. C3aR is expressed on various tissues and leucocytes including basophils, neutrophils, mast cells, eosinophils and activated T lymphocytes. Expression levels of C3aR on human cells varies significantly between donors. |
|
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles. | |
IgG1 |
Immunohistochemistry, Flow Cytometry, Immunohistochemistry (Frozen) | |
hC3aRZ1 | |
Unconjugated | |
PBS (pH 7.4) with 0.09% Sodium Azide | |
AZ3B, AZ3BC3a anaphylatoxin chemotactic receptor, C3a-R, C3AR, C3AR1, C3ARcomplement component 3 receptor 1, C3R1, complement component 3a receptor 1, Complement Component C3a R, Complement Component C3aR, HNFAG09 | |
Mouse | |
Protein G purified | |
RUO | |
719 | |
Human | |
Purified |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only
Spot an opportunity for improvement?Share a Content Correction